Developing immuno-oncology and ADC breakthrough therapies

80% of Cancer patients do not respond to approved immuno-oncology therapies.

Despite the progress and unprecedented efficacy of existing immunotherapy drugs, they are not effective for most patients. Patients fail to respond, or following encouraging initial response, develop resistance over time. At Nectin, we have discovered tumor escape and resistance mechanisms and are developing new candidates designed to overcome resistance to currently available therapies.

Nectin’s pipeline includes innovative first-in-class and best-in-class programs, utilizing internal expertise as well as collaborative efforts.

Diverse pipeline of targeted immunotherapies including novel immuno-oncology (IO) antibodies and ADCs.

PVR expression is emerging as an important rate-limiting factor for approved ICI’s. Our anti-PVR asset is currently in phase 1 of its clinical trial.

Get In Touch

If you share our passion for developing novel therapeutics to address difficult-to-treat cancers or would like to hear more about our current clinical trial and drug pipeline, please fill out this form below: